Acta diabetologicaOct 14, 2026

Do GLP-1 receptor drugs cause hair loss, have no real effect, or might they help with it?

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 15, 2026

Abstract

Hair loss is reported as an adverse event associated with incretin-based therapies like semaglutide, tirzepatide, and retatrutide.

The review consolidates evidence regarding hair loss prevalence linked to these therapies.
Mechanistic pathways that may explain hair loss are discussed.
The clinical course of hair loss in patients receiving these treatments is summarized.

Simplified

Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual/triple agonists, have revolutionized the management of obesity and type 2 diabetes. However, hair loss has emerged as an adverse event in clinical practice. This review synthesizes the evidence on the prevalence, mechanistic pathways, and clinical course of hair loss associated with semaglutide, tirzepatide, and retatrutide.

Full Text

Full text is available at the source.

View Full Text ↗

Do GLP-1 receptor drugs cause hair loss, have no real effect, or might they help with it?

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief